1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Physician Views: Five key pre-ASCO questions on the immuno-oncology race

Physician Views: Five key pre-ASCO questions on the immuno-oncology race

  • May 2014
  • ID: 2171803
  • Format: PDF
  • Firstword Pharma


The annual meeting of the American Society of Clinical Oncology (ASCO) will take place between May 30 and June 3, and for the second year in succession, conference headlines will be dominated by developments in the immuno-oncology (IO) space.

Data presented at last year's ASCO meeting acted as the catalyst for bullish commercial projections for the first generation of IO products, which include Bristol-Myers Squibb's already marketed Yervoy (ipilimumab; for melanoma) and the PD-1/PD-L1 inhibitors being developed by AstraZeneca, Bristol-Myers Squibb, Merck & Co. and Roche (which are initially being developed for melanoma, lung, renal and bladder cancer).

Analysts are now confidently predicting that the market for these products could be worth around $30 billion and potentially more, given that combinational use of IO therapies may facilitate expansion in multiple tumour types that are not yet being studied.

Focus in 2014 will not only be sharpened on new data presented at ASCO, but also the regulatory arena, with Merck potentially set to become the first company to secure approval for a PD-1/PD-L1 inhibitor; MK-3475 for the treatment of third-line melanoma. This could prove to be an important landmark in the race to translate R&D potential into commercial superiority.

Bristol-Myers Squibb retains pole position in the eyes of most analysts and observers, this status formed in part by the impressive combination data it presented for nivolumab and Yervoy at last year's ASCO conference in melanoma.

The reality, however, is that the race to market has become tighter over the past 12 months; failure of the nivolumab and Yervoy combination to showcase similarly impressive data in non-small-cell lung cancer (NSCLC) patients has demonstrated that there is still much to play for, while licensing deals, collaborations and acquisitions have helped to accelerate strategies designed to identify key combinations in the IO space.

Ahead of this year's ASCO meeting, FirstWord is polling US and EU5-based oncologists to ask them five key questions about the IO development space...

How their expectations for IO therapies being developed for melanoma, non-small-cell lung cancer (NSCLC) and renal cell carcinoma (RCC) have evolved over the past 12 months?
Which IO product/regimen – and for what indication – excites them the most based on currently available data?
To what percentage of first-line melanoma patients they would consider prescribing Merck's MK-3475 if approved for third-line (Yervoy-refractory) melanoma patients (based on available clinical data)?
How significant a role they anticipate PD-L1 expression to play in shaping the use of PD-1/PD-L1 antibodies for the treatment of NSCLC?
How significant a role they anticipate Yervoy to play in combination with PD-1/PD-L1 inhibitors in tumour types outside of melanoma?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on